Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2007
11/07/2007EP1852505A1 Mutations in ion channels
11/07/2007EP1852503A1 Il-13 production inhibitor
11/07/2007EP1852432A1 Nitrogenous heterocyclic compound and medicinal use thereof
11/07/2007EP1852423A1 Crystal of 4(3h)-quinazolinone derivative
11/07/2007EP1852420A1 Indole compound and use thereof
11/07/2007EP1852129A1 Remedy for irritable bowel syndrome
11/07/2007EP1852128A1 An anti HSP90 antibody
11/07/2007EP1852123A2 Activation and inhibition of the immune system
11/07/2007EP1852113A2 Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
11/07/2007EP1852111A1 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
11/07/2007EP1850851A2 Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines
11/07/2007EP1850838A2 Inhibition or treatment of dyskinesia
11/07/2007EP1790357A4 Perorally administrable antimicrobial composition
11/07/2007EP1553831A4 Process for screening fungitoxic compounds
11/07/2007EP1523486B1 Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
11/07/2007EP1520175B1 Oncolytic viruses as phenotyping agents for neoplasms
11/07/2007EP1423707B1 Methods of screening molecules that are used to prevent cardiovascular diseases
11/07/2007EP1401408A4 Controlled heat induced rapid delivery of pharmaceuticals from skin depot
11/07/2007EP1374901B9 Graft rejection suppressors
11/07/2007EP1161687B1 Grb7 family proteins and the insulin receptor for screening novel medicines.
11/07/2007EP0814785B1 Use of nitric oxide donors or nitric oxide inhibitors for regulating cervical dilatation and extensibility
11/07/2007CN101068916A Use of atazanavir for improving the pharmacokinetics of drugs metabolized by UGT1A1
11/07/2007CN101068570A Use of dipyridamole for treatment of resistance to platelet inhibitors
11/07/2007CN101067135A Novel oligonucleotides and use of oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments, as depigmentation agents
11/07/2007CN101066458A Application of cell nucleus targeting administration system capable of reversing tumor cell resistance
11/07/2007CN101066454A Solid tumor treating medicine composition
11/07/2007CN101066453A Solid tumor treating medicine composition
11/07/2007CN101066452A Solid tumor treating medicine composition containing
11/07/2007CN101066451A Solid tumor treating medicine composition containing dicloethamine
11/07/2007CN101066279A Chewing tablet of proton pump inhibitor
11/07/2007CN101066276A Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
11/07/2007CN101066245A Orally taken emulsion and its prepn
11/07/2007CN100346831C Combination of a PDE inhibitor and a leukotriene receptor antagonist
11/07/2007CN100346829C Adjuvant compsn comprising immunostimulatory oligonucleotide and tocol
11/07/2007CN100346823C Enamel matrix protein compositions for modulating immune response
11/07/2007CN100346822C Leukocyte inactivation module
11/07/2007CN100346794C Method of reducing toxicity of anticancer agents
11/07/2007CN100346772C Devices for delivery of drugs having antiprogestinic properties
11/06/2007US7291709 LSR (Lipolysis Stimulated Receptor); for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension
11/06/2007US7291650 Breast cancer ; therapy containing plant extracts
11/06/2007US7291637 4,7-Methano--, ethano-, oxy- or thio- indazol-3-ones or benzisothiazol-3-ones in which the S is mono- or dioxygenated, e.g., 3a,4,7,7a-tetrahydro-4,7-methano-1,2-benzisothiazol-3(2H)-one-1,1-dioxide; treatment of diseases such as cancer and immune disorders
11/06/2007US7291635 Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents
11/06/2007US7291630 Azaindoles as inhibitors of c-Jun N-terminal kinases
11/06/2007US7291622 Administering a 4-Amino-2-[1-(o-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinylcarbamate derivative, optionally mixed with an organic nitrate or NO donor or a cGMP inhibitor for treating sexual dysfunction
11/06/2007US7291619 Melanocortin receptor agonists
11/06/2007US7291613 Inhibitors of p38 kinase
11/06/2007US7291608 Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
11/06/2007US7291495 β-Secretase variant
11/06/2007US7291492 Histone deactylase for use in identifying modulators for prevention and treatment of cell proliferative disorders
11/06/2007US7291458 Leptin-mediated gene-induction
11/06/2007US7291352 Nut extract having different alkaloid profile; reduced level of carcinogens; supercritical CO2 extraction; maintaining nutraceutical effects; rapidly dissolving tablets
11/06/2007US7291344 Administering a botulinum toxin
11/06/2007US7291332 Inflammatory mediator antagonists
11/06/2007US7291330 MD-1 inhibitors as immune suppressants
11/06/2007US7291328 Method to enhance fat content in the milk of a diary cow
11/06/2007US7291327 Compositions and methods for inhibiting pathogenic growth
11/06/2007CA2363713C Lantibiotic
11/06/2007CA2353527C Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
11/01/2007WO2007123699A1 Methods and compositions for modulating melanogenesis by using a mclr agonist
11/01/2007WO2007123234A1 Antiepileptic action enhancer
11/01/2007WO2007123233A1 Gene associated with arteriosclerotic disease, and use thereof
11/01/2007WO2007123186A1 Pharmaceutical product
11/01/2007WO2007123126A1 Agent for improving decreased exercise tolerance in chronic heart failure
11/01/2007WO2007122815A1 Bivalent antibody directed against bir1
11/01/2007WO2007122419A2 Therapeutic method for glycaemic control
11/01/2007WO2007122382A2 Lycopene for the treatment of metabolic dysfunction
11/01/2007WO2007121546A1 Use of mas-g-protein-coupled receptor agonists in the treatment of the metabolic syndrome, its components and its complications
11/01/2007WO2007089907A3 Cationic steroid antimicrobial compositions and methods of use
11/01/2007WO2007076422A3 Antibodies against interleukin-22 binding protein and its uses
11/01/2007WO2007072503A3 Combinations for managing inflammation and associated disorders
11/01/2007WO2007072169A3 Pharmaceutical combination for the treatment of luts comprising a pde5 inhibitor and a muscarinic antagonist
11/01/2007WO2007053189A3 Compositions and methods for altering immune function
11/01/2007WO2006135738A3 Devices from prion-like proteins
11/01/2007WO2006131326B1 Novel use of (-)-epigallocatechin gallate
11/01/2007WO2005025490A3 Novel polyol macrolide antitumor-antibiotics from the novel marine actinomycete strain cnq140
11/01/2007US20070255238 Hemostatic Polymer Useful for Rapid Blood Coagulation and Hemostasis
11/01/2007US20070254031 Rapidly disintegrable solid preparation
11/01/2007US20070253959 Vascular endothelial cell growth factor antagonists
11/01/2007US20070253955 Methods for altering fertility
11/01/2007US20070253946 Axon Regeneration Promoter
11/01/2007US20070253943 Compositions for Topical Treatment
11/01/2007US20070253929 Derivatives of growth hormone and related proteins, and methods of use thereof
11/01/2007US20070253906 Identifying Amyloid precurser protein lowering agents; non-steroidal anti-inflammatory drug (NSAID); Alzheimer's disease
11/01/2007US20070253905 Abeta42 LOWERING AGENTS
11/01/2007CA2649628A1 Pharmaceutical product
11/01/2007CA2645633A1 Combinations of therapeutic agents for treating cancer
10/2007
10/31/2007EP1849802A2 Methods for altering fertility
10/31/2007EP1849797A2 Peptidomimetic protease inhibitors
10/31/2007EP1849795A1 1-substituted-7-( -d-glycopyranosyloxy)(aza)indole compound and pharmaceutical containing the same
10/31/2007EP1849480A2 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
10/31/2007EP1849478A2 Inflammatory mediator antagonists
10/31/2007EP1849471A1 Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and S-adenosylmethionine
10/31/2007EP1849470A1 Anticancer drug containing alpha, alpha, alphatrifluorothymidine and thymidine phosphorylase inhibitor
10/31/2007EP1849468A2 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
10/31/2007EP1848717A2 6-ether/thioether-purines as topoisomerase ii catalytic inhibitors and their use in therapy
10/31/2007EP1848438A2 Diaminophenothiazine compositions and uses thereof
10/31/2007EP1848418A2 Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection
10/31/2007EP1848400A1 Analgesic compositions
10/31/2007EP1496896A4 Inhibitors of akt activity
10/31/2007EP1455831B1 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
1 ... 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 ... 1151